Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD

Blood (2018) 132 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2018-99-115680

Published: 2018

Journal Articles

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Thierry Facon, Sagar Lonial, MD, Brendan M Weiss, MD, Attaya Suvannasankha, MD, Joseph Fay, Bertrand Arnulf, Jainulabdeen J Ifthikharuddin, Carla de Boer, Jianping Wang, Kaida Wu, Ajai Chari, Suzanne Lentzsch, Jordan Schecter, Amrita Krishnan, MD

Blood (2017) 130 (Supplement 1): 1824.

https://doi.org/10.1182/blood.V130.Suppl_1.1824.1824

Published: 2017

Journal Articles

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Attaya Suvannasankha, MD, Rafat Abonour, MD, Sherif Farag, MD PhD, Rebecca W. Silbermann, MD, Sariya Wongsaengsak, MD, Mary Helen Cangany, RN, Anita Rush-Taylor, RN, Mark Tann, MD, Sandra K Althouse, PhD, Susan M Perkins, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1826.

https://doi.org/10.1182/blood.V130.Suppl_1.1826.1826

Published: 2017

Journal Articles

Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D

Attaya Suvannasankha, MD, Colin D Crean, Douglas R Tompkins, Jesus Delgado-Calle, PhD, Teresita M Bellido, PhD, G. David Roodman, MD PhD, John M Chirgwin, PhD

Blood (2016) 128 (22): 4439.

https://doi.org/10.1182/blood.V128.22.4439.4439

Published: 2016

Journal Articles

TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients

Craig C Hofmeister, MD MPH, Jesus G. Berdeja, MD, David H. Vesole, MD PhD, Attaya Suvannasankha, MD, Tracy Parrott, Rafat Abonour, MD

Blood (2015) 126 (23): 3052.

https://doi.org/10.1182/blood.V126.23.3052.3052

Published: 2015

Journal Articles

Phase I/II Study of Lenalidomide and High Dose Melphalan As Preparative Regimen in Autologous Transplant in Myeloma: Report of Phase II Efficacy and Safety Data

Attaya Suvannasankha, MD, Sherif Farag, MD PhD, Rebecca Silbermann, MD, Mary Cangany, RN, Anita Rush-Taylor, RN, Robin O'Bryant, RN, Lisa Wood, RN, Jean Pearson, Sarah Singleton, Andrea Bradley, Sandra Althouse, Susan Perkins, PhD, Deb Estes, RN, Rafat Abonour, MD

Blood (2015) 126 (23): 3193.

https://doi.org/10.1182/blood.V126.23.3193.3193

Published: 2015

Journal Articles

Neonatal Mouse Bone Supports Growth Of Primary Myeloma Cells Ex Vivo and Assessment Of Responses To Antimyeloma Drugs

Attaya Suvannasankha, MD, Douglas R Tompkins, MS, Kateryna Petyaykina, Colin D. Crean, Keith W Condon, PhD, G. David David Roodman, MD, PhD, John M Chirgwin, PhD

Blood (2013) 122 (21): 1893.

https://doi.org/10.1182/blood.V122.21.1893.1893

Published: 2013

Journal Articles

Role Of CD166 In Multiple Myeloma Cell Homing To The Bone Marrow Microenvironment and Disease Progression

Linlin Xu, Christophe Machal, Hao Wu, Bradley Poteat, Colin D. Crean, Angelo A. Cardoso, MD, PhD, John M Chirgwin, PhD, Helmut Hanenberg, MD, Khalid S. Mohammad, M.D. Ph.D., Attaya Suvannasankha, MD, Edward F Srour, PhD

Blood (2013) 122 (21): 3102.

https://doi.org/10.1182/blood.V122.21.3102.3102

Published: 2013

Journal Articles

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

Nikhil C. Munshi, MD, Rafat Abonour, MD, Joseph T. Beck, MD, William Bensinger, MD, Thierry Facon, MD, Keith Stockerl-Goldstein, MD, Rachid Baz, MD, David S Siegel, MD, PhD., Kai Neben, MD, Sagar Lonial, MD, Attaya Suvannasankha, MD, Sanela Bilic, PharmD, Sandra Chica, Subhendu Mukhopadhyay, Randi Isaacs, Sundar Jagannath, MD

Blood (2012) 120 (21): 331.

https://doi.org/10.1182/blood.V120.21.331.331

Published: 2012

Journal Articles

A Phase I/II Trial Combining High-Dose Lenalidomide with Melphalan and Autologous Transplant for Multiple Myeloma: A Report of the Phase I Dose-Finding Study.

Attaya Suvannasankha, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Rebecca Silbermann, M.D., Robin Obryant, RN, Lisa l Wood, RN, Abigail Huljak, Angie Secrest, Colin D. Crean, Rafat Abonour, MD

Blood (2012) 120 (21): 3146.

https://doi.org/10.1182/blood.V120.21.3146.3146

Published: 2012

Journal Articles

Assessment of Free Light Chains in the Ascites and Pleural Effusion in Patients with Multiple Myeloma: A Report of 2 Cases

Sawsan Rashdan, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Rafat Abonour, MD, Attaya Suvannasankha, MD

Blood (2011) 118 (21): 5078.

https://doi.org/10.1182/blood.V118.21.5078.5078

Published: 2011

Journal Articles

A Potential Biomarker Panel of Multiple Myeloma Identified Using Label-Free Mass Spectrometry-Based Quantitative Proteomics

Attaya Suvannasankha, MD, Colin D. Crean, Heather M. Sahm, Rafat Abonour, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Mu Wang, PhD

Blood (2011) 118 (21): 2890.

https://doi.org/10.1182/blood.V118.21.2890.2890

Published: 2011

Journal Articles

Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM

Attaya Suvannasankha, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Stephen Harding, PhD, Brian GM Durie, MD, Rafat Abonour, MD

Blood (2010) 116 (21): 2986.

https://doi.org/10.1182/blood.V116.21.2986.2986

Published: 2010

Journal Articles

Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results

Sherif Farag, MD, PhD, Shuhong Zhang, PhD, Attaya Suvannasankha, MD, Jing Liang, MD, Robyn O'Bryant, RN, Wood Lisa, RN, Sushil Gupta, PhD, Mark Bray, PhD, Carolyn Fowler Sidor, MD, Rafat Abonour, MD

Blood (2010) 116 (21): 1957.

https://doi.org/10.1182/blood.V116.21.1957.1957

Published: 2010

Journal Articles

Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis.

Rajasubramaniam Shanmugam, PhD., Annique Wilson-Weekes, MS, Hamid Sayar, MD, Attaya Suvannasankha, MD, Angelo A. Cardoso, MD., PhD, Katie J Sargent, RN, Larry D. Cripe, MD, Dhananjaya V Kalvakolanu, PhD., H. Scott Boswell, MD

Blood (2009) 114 (22): 2387.

https://doi.org/10.1182/blood.V114.22.2387.2387

Published: 2009

Journal Articles

Multiple Myeloma Derived Factors Generate Tolerogenic Dendritic Cells by Activation of STAT3: A Potential Target for Immunotherapy.

Yaser Homsi, MD, Li Chen, MD, Shuhong Zhang, PhD, Jing Liang, Attaya Suvannasankha, MD, Rafat Abonour, MD., Sherif Farag, MD, PhD

Blood (2009) 114 (22): 3031.

https://doi.org/10.1182/blood.V114.22.3031.3031

Published: 2009

Journal Articles

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

Rafat Abonour, Hayley Knollman, Attaya Suvannasankha, MD, Menggang Yu, Rebecca Britton, Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Jennifer E. Schwartz, MD, FRCP(C), Michael Robertson, MD, Kenneth Cornetta, MD, Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 1224.

https://doi.org/10.1182/blood.V114.22.1224.1224

Published: 2009

Journal Articles

The Role of the Antiapoptotic Protein c-FLIP in Multiple Myeloma.

Colin D. Crean, Genglin Zhang, Lauren B VanRyckeghem, BS, Helmut Hanenberg, Sherif Farag, MBBS, PhD, Rafat Abonour, Attaya Suvannasankha, MD

Blood (2009) 114 (22): 1966.

https://doi.org/10.1182/blood.V114.22.1966.1966

Published: 2009

Journal Articles

Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.

Don Benson, MD, PhD, Craig C. Hofmeister, MD, Swaminathan Padmanabhan, MD, MBBS, Rafat Abonour, Attaya Suvannasankha, MD, Alain Mita, Patrick Squiban, MD, Megan K Smith, MS, CNP, RN, Courtney E Bakan, Marc Marzetto, Pascale Andre, PhD, Jerome Tollier, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 2880.

https://doi.org/10.1182/blood.V114.22.2880.2880

Published: 2009

Journal Articles

Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients.

Attaya Suvannasankha, MD, Sherif Farag, MBBS, PhD, Robin A O'Bryant, RN, Lisa L Wood, RN, Rafat Abonour

Blood (2009) 114 (22): 2882.

https://doi.org/10.1182/blood.V114.22.2882.2882

Published: 2009

NARROW

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D

TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients

Phase I/II Study of Lenalidomide and High Dose Melphalan As Preparative Regimen in Autologous Transplant in Myeloma: Report of Phase II Efficacy and Safety Data

Neonatal Mouse Bone Supports Growth Of Primary Myeloma Cells Ex Vivo and Assessment Of Responses To Antimyeloma Drugs

Role Of CD166 In Multiple Myeloma Cell Homing To The Bone Marrow Microenvironment and Disease Progression

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

A Phase I/II Trial Combining High-Dose Lenalidomide with Melphalan and Autologous Transplant for Multiple Myeloma: A Report of the Phase I Dose-Finding Study.

Assessment of Free Light Chains in the Ascites and Pleural Effusion in Patients with Multiple Myeloma: A Report of 2 Cases

A Potential Biomarker Panel of Multiple Myeloma Identified Using Label-Free Mass Spectrometry-Based Quantitative Proteomics

Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM

Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results

Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis.

Multiple Myeloma Derived Factors Generate Tolerogenic Dendritic Cells by Activation of STAT3: A Potential Target for Immunotherapy.

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

The Role of the Antiapoptotic Protein c-FLIP in Multiple Myeloma.

Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.

Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only